Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunogen Inc (NQ: IMGN )

15.97 -0.19 (-1.14%)
Streaming Delayed Price Updated: 2:17 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Immunogen Inc

< Previous 1 2 3 4 5 6 Next >
These Three Biotech Stocks Are Trading At A Discount
Investors exposed to the biotech sector have seen mixed results this year. 
Via Talk Markets
Where Immunogen Stands With Analysts
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News
CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating
Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. 
Via Investor's Business Daily
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
What 4 Analyst Ratings Have To Say About Immunogen
Via Benzinga
10 Analysts Have This to Say About Immunogen
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Sutro Biopharma's Lead Ovarian Cancer Candidate Is A Game Changer, Analyst Sees Huge Upside
Oppenheimer initiated coverage on Sutro Biopharma Inc (NASDAQ: STRO), representing around 200% potential upside.  
Via Benzinga
Analyst Ratings for Immunogen
Via Benzinga
BMO Capital Maintains Outperform Rating for Immunogen: Here's What You Need To Know
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
Via Benzinga
These 8 Stocks Are Outperforming Nvidia In 2023
Carvana has surged 1,001%, leading huge winners this year. 
Via Investor's Business Daily
Ovarian Cancer Player ImmunoGen Can Potentially Be Attractive M&A Target: JP Morgan
JP Morgan upgraded ImmunoGen Inc (NASDAQ: IMGN) from Neutral to Overweight with a price target of $22, up from $9, based on insights gathered from a recent physician survey, which focused on the... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
Finding the best pharma stocks to buy takes a little effort, but it will pay of with these seven long-term winners. 
Via InvestorPlace
Verizon To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Tuesday
Stifel raised the price target for Hersha Hospitality Trust (NYSE: HT) from $8.75 to $10. Stifel analyst Simon Yarmak downgraded the stock from Buy to Hold. Hersha Hospitality Trust shares fell 0.5% to... 
Via Benzinga
ImmunoGen Inks Pact With Takeda To Develop ELAHERE Ovarian Cancer Drug In Japan
ImmunoGen, Inc. (NASDAQ: IMGN) inked pacts with Takeda Pharmaceutical Company Limited (NYSE: TAK) to develop and  
Via Benzinga
5 Meme Stocks to Sell Immediately, According to AI
As we move into September, the MarketMaster AI is flashing warning signals about risky equities. Sell these meme stocks right now. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
These Are the ONLY 3 Biotech Stocks to Consider in August 2023
These biotech stocks to buy represent tremendous bets and are essentially fueling innovation and portfolio growth at the same time. 
Via InvestorPlace
How To Invest In The Healthcare Sector
If things go wrong with some healthcare companies, investors often justify why they stay in the stock. And when things go right, they can go right in a hurry. Mersana Therapeutics is an example of how... 
Via Talk Markets
7 A-Rated Biotech Stocks for Your August Buy List
Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge. 
Via InvestorPlace
ImmunoGen Outperforms Q2 Revenue Expectations Bolstered By Strong Elahere Sales
ImmunoGen Inc (NASDAQ: IMGN) reported Q2 revenues of $83.15 million, surpassing the consensus of $42.84 million and  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the week with a breakdown of the biggest pre-market stock movers worth watching for Monday morning! 
Via InvestorPlace
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
Earnings Scheduled For July 31, 2023
Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.